期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Characterization of natural peptides in Pheretima by integrating proteogenomics and label-free peptidomics
1
作者 xiaoxiao luo Qirui Bi +10 位作者 Dongdong Huang Yun Li Changliang Yao Jianqing Zhang Wenlong Wei Jiayuan Li Zhenwei Li Jingxian Zhang Shen Ji Yurong Wang De-an Guo 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2023年第9期1070-1079,共10页
Pheretima,also called“earthworms”,is a well-known animal-derived traditional Chinese medicine that is extensively used in over 50 Chinese patent medicines(CPMs)in Chinese Pharmacopoeia(2020 edition).However,its zool... Pheretima,also called“earthworms”,is a well-known animal-derived traditional Chinese medicine that is extensively used in over 50 Chinese patent medicines(CPMs)in Chinese Pharmacopoeia(2020 edition).However,its zoological origin is unclear,both in the herbal market and CPMs.In this study,a strategy for integrating in-house annotated protein databases constructed from close evolutionary relationship-sourced RNA sequencing data from public archival resources and various sequencing algorithms(restricted search,open search,and de novo)was developed to characterize the phenotype of natural peptides of three major commercial species of Pheretima,including Pheretima aspergillum(PA),Pheretima vulgaris(PV),and Metaphire magna(MM).We identified 10,477 natural peptides in the PA,7,451 in PV,and 5,896 in MM samples.Five specific signature peptides were screened and then validated using synthetic peptides;these demonstrated robust specificity for the authentication of PA,PV,and MM.Finally,all marker peptides were successfully applied to identify the zoological origins of Brain Heart capsules and Xiaohuoluo pills,revealing the inconsistent Pheretima species used in these CPMs.In conclusion,our integrated strategy could be used for the in-depth characterization of natural peptides of other animal-derived traditional Chinese medicines,especially non-model species with poorly annotated protein databases. 展开更多
关键词 PHERETIMA Natural peptides Label-free peptidomics PROTEOGENOMICS Animal derived medicine
下载PDF
Future of targeted therapy for gastrointestinal cancer:Claudin 18.2
2
作者 Qian Niu Jiamin Liu +2 位作者 xiaoxiao luo Beibei Su Xianglin Yuan 《Oncology and Translational Medicine》 CAS 2021年第3期102-107,共6页
The treatment of gastrointestinal cancer has always been a crucial research area,and targeted therapy has been receiving increasing attention.At present,the effect of targeted therapy is unsatisfactory for gastric can... The treatment of gastrointestinal cancer has always been a crucial research area,and targeted therapy has been receiving increasing attention.At present,the effect of targeted therapy is unsatisfactory for gastric cancer.Thus,the discovery of new targets is crucial.Claudin 18.2(CLDN18.2),a member of the claudin family,belongs to the tight junction protein family that controls the flow of molecules between cell layers.CLDN18.2 expression has been discussed in many studies.In recent years,there have been many studies on targeted therapy with CLDN18.2-ideal monoclonal antibody 362.Furthermore,CLDN18.2-specific chimeric antigen receptor T therapy has been used for CLDN18.2-positive tumors,such as gastric and pancreatic cancers.Considerable research has been focused on CLDN18.2.CLDN18.2,a newly discovered marker for precise targeted therapy of gastric cancer,could offer new hope for the treatment of gastric cancer. 展开更多
关键词 gastrointestinal cancer claudin 18.2(CLDN18.2) targeted therapy ideal monoclonal antibody 362(IMAB362) chimeric antigen receptor(CAR)T cells treatment
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部